Pharma News India Weekly: GLP-1 Patent War, Price Crisis & Supply Chain Chaos (March 9-14, 2026) Published • March 14, 2026
The Indian pharmaceutical industry just navigated one of its most challenging weeks in recent memory. Between landmark legal rulings, unprecedented raw material price hikes, and supply chain disruptions from the Iran conflict, here's everything you need to know.
📋 Week At A Glance
Top StoryImpactDelhi HC allows Dr. Reddy's to export semaglutide50+ generics poised to enter at 1/3rd priceAPI prices surge 20-106%Glycerin +64%, Paracetamol +26%45,000 containers stranded$1.5 billion export cargo affectedIndia-Uzbekistan pharma corridor launchedTargeting $7-10 billion Eurasian marketCDSCO bans GLP-1 surrogate adsCelebrity obesity campaigns halted
⚖️ GLP-1 Patent War: Dr. Reddy's Wins Major Victory
Date: March 9-10
The Delhi High Court delivered a landmark ruling allowing Dr. Reddy's Laboratories to manufacture and export semaglutide to countries where Novo Nordisk lacks patent protection.
What Happened:
A division bench dismissed Novo Nordisk's appeal against a December 2025 order, observing that the company's species patent appeared "susceptible to revocation on grounds of obviousness." The court noted that semaglutide would be obvious from teachings in Novo's earlier genus patent, which expired in 2024.
Why It Matters:
Novo's Indian patent expires March 20—just days away. After that, over 50 branded generics are expected to flood the market at one-third to one-fifth the innovator price (₹3,000-5,000 monthly vs current ₹10,000-16,000).
Market Impact:
The GLP-1 segment recorded 177% sales growth on a moving annual turnover basis to ₹1,446 crore in February 2026. Eli Lilly's Mounjaro retained top spot as India's best-selling drug for the fifth consecutive month with ₹117 crore in February sales.
Expert Concern:
As prescribing shifts from endocrinologists to general practitioners, patient profiling and therapy adherence monitoring become critical to prevent dropouts.
📈 Raw Material Crisis: Prices Through the Roof
The Iran conflict is hitting pharmaceutical supply chains hard. Here's the latest data on price increases (December 2025 to March 2026):
IngredientIncreaseUseThiocolchicide▲ 106%Muscle relaxantGlycerin▲ 64%Solvent, excipientNimesulide▲ 53%Pain reliefDeflazacort▲ 50%SteroidClobetasol Propionate▲ 47%Skin treatmentAmoxicillin Trihydrate▲ 45%AntibioticParacetamol▲ 26%Fever, painDiclofenac Sodium▲ 25-30%Anti-inflammatoryCiprofloxacin▲ 20-30%AntibioticSolvents (IPA, Acetone)▲ 20-30%Manufacturing
Why Prices Are Rising:
1. Rupee Depreciation: Most pharmaceutical raw materials are globally traded in dollars. The weakening rupee automatically increases import costs for Indian manufacturers.
2. Petroleum-Linked Solvents: Solvent prices are closely tied to crude oil derivatives. With oil crossing $115/barrel, costs surged 20-30% in a single week.
3. Container Shortages: Vessels and containers are delayed or stuck due to security concerns, affecting raw material movement from China—India's largest supplier.
4. Opportunistic Pricing: Some suppliers are taking advantage of the crisis to push prices further.
Industry Response:
The Federation of Pharma Entrepreneurs has urged NPPA to allow price hikes under DPCO 2013 Para 19. "The pharma industry being highly price regulated, it is difficult to absorb unprecedented increase in price of inputs," said Harish Jain, national president.
Who Gets Hit Hardest:
Small and medium manufacturers are most vulnerable. Unlike large players, MSMEs cannot absorb these costs or easily pass them on due to price controls. If the conflict prolongs, medicine availability could be affected.
🚢 Supply Chain Disruption: 45,000 Containers Stranded
The Scale:
Approximately 40,000-45,000 Indian containers are stranded in international waters or at ports, affecting export cargo worth $1-1.5 billion. Around 80% are already in transit.
Cost Explosion:
- Normal freight: $800-1,500 per container
- War surcharges: $3,000-5,000 extra
- Bunker fuel: Up 35% in one week
- Shipping lines imposing $100-200 per TEU emergency charges
Maersk Statement: "The evolving security situation in West Asia continues to create significant challenges for logistics and supply chains. Nearly 20% of global fuel shipments passes through the Strait of Hormuz."
Medical Devices Hit:
Polypropylene prices surged ₹55/kg since December. Gas rationing by Adani Total Gas is impacting syringe and IV bag manufacturers, with supplies restricted to 40% of contracted quantity. "Even in Covid times, we have never witnessed this price gouging," said an industry expert.
Government Relief:
CBIC Guidelines (March 8):
- Vessels permitted to berth only at same Indian port of departure
- Back-to-town facility allowed for exporters
- Export incentives recovered manually if already disbursed
- Guidelines valid for 15 days initially
DGCA Directives: All shipping lines directed to refrain from "predatory, non-transparent and opportunistic pricing practices."
Covid-era Support Discussed: The government is considering loan moratoriums, extended repatriation timelines, and relaxed bank overdraft rules for affected exporters.
🌍 Trade Expansion: India-Uzbekistan Pharma Corridor Launched
Date: March 9
Amidst the crisis, strategic moves continued. India and Uzbekistan launched a structured pharmaceutical and nutraceutical trade corridor targeting the $7-10 billion Eurasian healthcare market.
What It Offers:
- Regulatory harmonization
- Investment facilitation
- Market access for Indian manufacturers
- Joint ventures and supply chain integration
Launch Event: Commercial operations begin at Pharma Eurasia 2026 in Tashkent (May 20-22), bringing together manufacturers, regulators, and distributors across CIS countries.
FTA Update:
Commerce Minister Piyush Goyal highlighted that India's nine FTAs signed in four years have opened nearly two-thirds of global trade to Indian pharma. Negotiations are progressing well with GCC and Eurasia.
⚠️ Regulatory Crackdown: CDSCO Bans GLP-1 Surrogate Ads
Date: March 11
The Central Drugs Standard Control Organisation issued a strong advisory prohibiting pharmaceutical companies from using "so-called awareness campaigns" to promote GLP-1 drugs.
The Context:
Eli Lilly and Novo Nordisk had launched aggressive multimedia campaigns featuring celebrities like Boman Irani and Ratna Pathak Shah, framed as obesity awareness initiatives. The regulator viewed these as surrogate advertising for prescription-only drugs.
The Warning:
"Any promotional activity, including surrogate advertisements for prescription-only drugs shall be viewed seriously and may be treated as irrational or misleading marketing practice."
Also in Regulatory News:
NPPA launched an investigation into e-pharmacy dynamic pricing, targeting:
- Location-based pricing algorithms
- Inflated base prices with discount claims
- Real-time transaction monitoring through IPDMS 2.0
💼 Corporate News: Kedaara to Sell Universal NutriScience
Date: March 11
Kedaara Capital is preparing to sell Universal NutriScience for an expected ₹3,000 crore valuation. Investment bank Rothschild has been appointed to advise.
Company Snapshot:
- Formed 2021: Acquired 16 nutraceutical brands from Sanofi India for ₹587 crore
- Portfolio: Includes Seacod, top-selling cod liver oil brand
- FY25 revenue: ₹230 crore (EBITDA ₹61 crore)
- FY26 estimate: ₹350-400 crore (EBITDA ~₹100 crore)
Sector Context: India's nutraceuticals sector, valued at around $8 billion, is projected to grow at 11% CAGR through 2027.
Other Corporate News:
Aurobindo Pharma: Received VAI classification from USFDA for Andhra Pradesh unit—objectionable conditions found but no regulatory action planned.
Cipla: Recalled 400+ cartons of Nilotinib capsules (150 mg and 200 mg) in US due to "failed tablet/capsule specifications." Class III voluntary recall initiated February 18.
Bharat Biotech: Celebrated 30 years, delivering 9 billion vaccine doses to 125+ countries. Played catalytic role in developing Hyderabad's Genome Valley.
ACG: Became world's first pharma packaging company in WEF's Global Lighthouse Network with 40% lead time reduction, 71% defect reduction, and 31% energy reduction at Shirwal facility.
🔬 COVID Vaccine Compensation: SC Directs No-Fault Policy
Date: March 10
The Supreme Court directed the government to frame a no-fault compensation policy for individuals suffering serious adverse events following COVID-19 vaccination.
Scientific Breakthrough:
A NEJM study identified the molecular mechanism behind rare vaccine-induced blood clots (VITT). Antibodies from affected patients shared identical genetic features causing them to mistakenly target platelet factor 4 instead of viral protein VII.
🌐 International News Roundup (PharmaTimes, March 9-14)
Regulatory Approvals:
- MHRA approved deuruxolitinib for severe alopecia areata
- NHS to offer fezolinetant for menopause hot flushes following NICE recommendation
Clinical Trials:
- Aplagon dosed first patient in phase 2a peripheral arterial disease trial
- UCB reported bimekizumab superiority over risankizumab in psoriatic arthritis
- Kainova reported positive phase 1 data for DT-9081 in advanced solid tumours
- EnteroBiotix completed enrolment for EBX-102-02 trial in microbiome therapy
Appointments:
- Dr Michelle Morrow appointed CSO at Nucleome
- Dr Klaas Zuideveld named CEO at TECregen
- Rebecca Simmons appointed COO at Qureight
❓ Frequently Asked Questions
What are the top pharmaceutical trends for 2026?
GLP-1 market expansion with 50+ generic entrants, geopolitical supply chain resilience, API price inflation, digital manufacturing transformation, FTA-driven export growth, and regulatory crackdown on surrogate advertising.
What are the latest pharma news updates this week?
Delhi HC allowed Dr. Reddy's semaglutide exports, API prices surged 20-106%, 45,000 containers stranded, India-Uzbekistan pharma corridor launched, CDSCO banned GLP-1 surrogate ads, and Kedaara plans ₹3,000 crore Universal NutriScience sale.
What is happening in the pharmaceutical industry this week?
The industry is grappling with raw material inflation while navigating supply chain disruptions from the Iran conflict. Simultaneously, the GLP-1 market is heating up with legal victories for generic manufacturers and regulatory action against promotional campaigns.
Where can I find all weekly pharma industry news?
For comprehensive weekly updates on the Indian pharmaceutical industry, including market trends, policy changes, and corporate developments, visit GreenCrossIndia.com/blog.
How is the Iran war affecting Indian pharma?
The conflict has triggered: API price hikes of 20-106%, solvent cost increases of 20-30%, freight cost doubling with $3,000-5,000 war surcharges, 45,000 stranded containers, and potential ₹2,500-5,000 crore export losses if disruptions continue.
Will medicine prices increase in India?
Industry has urged NPPA to allow price hikes under DPCO 2013 Para 19 due to unprecedented input cost inflation. While companies are absorbing costs currently, prolonged conflict may force price revisions, particularly for non-scheduled medicines.
For daily updates, bookmark GreenCrossIndia.com/blog